What was filed
Following its 31 July 2026 board meeting, Sun Pharma filed unaudited standalone and consolidated results for the quarter ended 30 June 2026, together with a press release and earnings presentation. The results carry a limited review from S R B C & CO LLP, whose report states that nothing came to its attention indicating material misstatement. The company reports a single 'Pharmaceuticals' segment and consolidates 89 subsidiaries plus associates and a joint venture.
The filing notes the board meeting was ongoing and temporarily adjourned at the time of submission, with any remaining outcomes to follow.
The quarter in brief
Consolidated sales grew about 10% year-on-year, with reported net profit also higher. Management attributed the quarter to momentum in India and its Innovative Medicines portfolio. India formulation sales grew 16%, and the company said its India market share rose to 8.5% from 8.2%, per the Pharmarack MAT June-2026 report.
Not every region moved the same way. US formulation sales declined 9.7% to US$ 427 million, which the company said reflected a decline in generics — including lenalidomide — partially offset by growth in Innovative Medicines. Emerging Markets formulations rose 4.2%. The presentation put consolidated EBITDA margin at 28.9%, down from 31.1% a year earlier, and cited a net cash position of US$ 3.4 billion.
The Organon acquisition and exceptional items
The corporate event shaping this quarter is the pending acquisition of Organon & Co. Per the filing, on 27 April 2026 the Group entered a definitive agreement to acquire all outstanding shares of Organon for US$ 14.00 per share in an all-cash transaction with an enterprise valuation of US$ 11.75 billion, subject to approvals and closing conditions. The company said Organon shareholders approved the deal on 23 July 2026, and the managing director described it as on track to close in early 2027, with closing indicated by Q4 FY27.
The quarter's consolidated exceptional items included a Rs 1,670.0 million charge for due diligence, legal, filing and other acquisition-related costs tied to the Organon agreement, with the company noting further such costs are expected in later periods. A separate incremental cost was recognised under the New Labour Codes framework, effective 21 November 2025.